The safety and efficacy of BRENZAVVY have been evaluated in 23 clinical studies enrolling more than 5,000 adult participants.
BRENZAVVY has been clinically proven to reduce A1c.
Multiple Phase 2 and Phase 3 studies have shown that BRENZAVVY significantly reduces hemoglobin A1c and fasting blood sugar in adults with type 2 diabetes.
May Reduce Blood Pressure
Although BRENZAVVY has not received FDA approval for lowering blood pressure, modest decreases in blood pressure were observed in clinical studies of adults with type 2 diabetes. The reduction of blood pressure was durable over time and measured up to 96 weeks of treatment with BRENZAVVY 20 mg tablet versus placebo.
May Support Weight Loss
Although BRENZAVVY has not received FDA approval for weight loss, modest decreases in weight were observed in clinical studies. Adults with type 2 diabetes saw a reduction in body weight of 4 to 8 pounds on average after 24 weeks of treatment with BRENZAVVY 20 mg tablet, while patients in the same studies treated with placebo saw a reduction in body weight of up to 3 pounds on average.
